OBJECTIVE: To assess whether antibodies to human heat shock protein 60 (anti-huhsp60) or to mycobacterial heat shock protein 65 (anti-mhsp65) predict an adverse one year prognosis in patients admitted with acute cardiac chest pain. DESIGN: Prospective observational study. SETTING: Teaching hospital. PATIENTS: 588 consecutive emergency admissions of patients with acute chest pain of suspected cardiac origin. MAIN OUTCOME MEASURES: Anti-huhsp60 and anti-mhsp65 titres were assayed on samples drawn on the morning after admission. The end points after discharge were coronary heart disease death, non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, angiogram, or readmission with further cardiac ischaemic chest pain. RESULTS: During follow up after discharge (mean of 304 days, range 1-788 days), 277 patients had at least one of the study outcomes. Patients with increased titres of anti-huhsp60 had an adverse prognosis (hazard ratio 1.56 (95% confidence interval 1.09 to 2.23) comparing highest versus lowest quartiles, p = 0.015). Anti-mhsp65 titres were not predictive. CONCLUSIONS: Patients admitted with acute cardiac chest pain and increased titres of anti-huhsp60 had an adverse one year prognosis.
OBJECTIVE: To assess whether antibodies to human heat shock protein 60 (anti-huhsp60) or to mycobacterial heat shock protein 65 (anti-mhsp65) predict an adverse one year prognosis in patients admitted with acute cardiac chest pain. DESIGN: Prospective observational study. SETTING: Teaching hospital. PATIENTS: 588 consecutive emergency admissions of patients with acute chest pain of suspected cardiac origin. MAIN OUTCOME MEASURES: Anti-huhsp60 and anti-mhsp65 titres were assayed on samples drawn on the morning after admission. The end points after discharge were coronary heart disease death, non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, angiogram, or readmission with further cardiac ischaemic chest pain. RESULTS: During follow up after discharge (mean of 304 days, range 1-788 days), 277 patients had at least one of the study outcomes. Patients with increased titres of anti-huhsp60 had an adverse prognosis (hazard ratio 1.56 (95% confidence interval 1.09 to 2.23) comparing highest versus lowest quartiles, p = 0.015). Anti-mhsp65 titres were not predictive. CONCLUSIONS:Patients admitted with acute cardiac chest pain and increased titres of anti-huhsp60 had an adverse one year prognosis.
Authors: Amarilla Veres; George Füst; Marek Smieja; Matthew McQueen; Anna Horváth; Qilong Yi; Adrienn Bíró; Janice Pogue; László Romics; István Karádi; Mahavir Singh; Judy Gnarpe; Zoltán Prohászka; Salim Yusuf Journal: Circulation Date: 2002-11-26 Impact factor: 29.690
Authors: Satoru Hirono; Elena Dibrov; Cecilia Hurtado; Annette Kostenuk; Robin Ducas; Grant N Pierce Journal: Circ Res Date: 2003-09-18 Impact factor: 17.367
Authors: Tiina Huittinen; Maija Leinonen; Leena Tenkanen; Hanna Virkkunen; Matti Mänttäri; Timo Palosuo; Vesa Manninen; Pekka Saikku Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Olaimatu S Mahdi; Benjamin D Horne; Kelly Mullen; Joseph B Muhlestein; Gerald I Byrne Journal: Circulation Date: 2002-09-24 Impact factor: 29.690
Authors: George Füst; Katalin Uray; László Bene; Ferenc Hudecz; István Karádi; Zoltán Prohászka Journal: Cell Stress Chaperones Date: 2011-10-29 Impact factor: 3.667
Authors: S Janket; J H Meurman; A E Baird; M Qvarnström; P Nuutinen; L K Ackerson; J Hong; P Muthukrishnan; T E Van Dyke Journal: J Dent Res Date: 2010-02-22 Impact factor: 6.116
Authors: Attila Molvarec; Zoltán Derzsy; Judit Kocsis; Tamás Boze; Bálint Nagy; Krisztián Balogh; Veronika Makó; László Cervenak; Miklós Mézes; István Karádi; Zoltán Prohászka; János Rigó Journal: Cell Stress Chaperones Date: 2009-02-11 Impact factor: 3.667